Emeritus Professor, Medicine - Infectious Diseases, Stanford University Medical Center
Infectious Disease
Dr. Andrew Zolopa, MD
|
|
Give Review
Andrew Zolopa practices Infectious Disease. He studied medicine at David Geffen School of Medicine at UCLA. David Geffen School of Medicine at UCLA is a top medical university. David Geffen School of Medicine at UCLA is ranked 13 in research and 7 in primary care medicine He has 1 awards "CMS Meaningful Use Stage 1 Certification". Andrew Zolopa is a published physician as well. He has 12 publications published. The latest was: Clinical and Immunologic Predictors of Death After an Acute Opportunistic Infection: Results from ACTG A5164. He is registered with Medicare.
Publications
- Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy: A Randomized Phase 2 Study.
- Regulatory T cells and the risk of CMV end-organ disease in patients with AIDS.
- Evolution of HIV treatment guidelines in high and low-income countries: Converging recommendations.
- A randomized, double-blind comparison of single tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single tablet regimen efavirenz/emtricitabine/...
- Low Baseline CD4+ Count Is Associated With Greater Bone Mineral Density Loss After Antiretroviral Therapy Initiation.
- A randomized, double-blind comparison of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF for initial treat...
- Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor.
- Evaluation of high-protein supplementation in weight-stable HIV-positive subjects with a history of weight loss: a randomized, double-blind, multicenter trial.
- Clinical and Immunologic Predictors of Death After an Acute Opportunistic Infection: Results from ACTG A5164.
- Gender inequality and HIV transmission: a global analysis.
- Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.
Schools
University of California At Los Angeles
Santa Clara Vly Med Center
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Santa Clara Valley Medical Center -
David Geffen School of Medicine at UCLA
Hospital
-
Stanford Health Care
Drug Facts
| NPI NUMBER | 1447264130 | |
| NPPES Provider LastName | ZOLOPA | |
| NPPES Provider FirstName | ANDREW | |
| NPPES Provider ZIPCode | 943052200 | |
| NPPES Provider State | CA | |
| Specialty Description | Infectious Disease | |
| Total Claim Count | 616.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1447264130 |
| Last Name Of The Provider | ZOLOPA |
| First Name Of The Provider | ANDREW |
| View All |
Similar Doctors
|
|
Dr. Philip M. Grant, MD |